HYPERLIPIDEMIA IN CHILDHOOD NEPHROTIC SYNDROME

被引:21
|
作者
THABET, MAEH [1 ]
SALCEDO, JR [1 ]
CHAN, JCM [1 ]
机构
[1] VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,CHILDRENS MED CTR,DEPT PEDIAT,DIV NEPHROL,MCV STN,RICHMOND,VA 23298
关键词
NEPHROTIC SYNDROME; HYPERLIPIDEMIA; ATHEROSCLEROSIS; GLOMERULOSCLEROSIS;
D O I
暂无
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Hyperlipidemia is an important characteristic of nephrotic syndrome (NS). Elevation of plasma total cholesterol, or more specifically low-density lipoprotein cholesterol, is the major lipid abnormality in NS, although hypertriglyceridemia may develop as the disorder progresses. The pathophysiology of nephrotic hyperlipidemia is complex. The prevailing view is that both hepatic synthesis of lipids and of apolipoproteins is increased, and that the clearance of chylomicrons and very low-density lipoproteins is reduced. The precise contribution of increased lipogenesis and decreased lipid catabolism to hyperlipidemia, and their relationship to urinary protein loss, hypoalbuminemia and reduced serum oncotic pressure remain controversial. There are two potential risks of elevated plasma lipids: atherosclerosis and progression of glomerular injury. Although neither of these complications has been proved with certainty, there is growing evidence that both may be long-term consequences of NS. Therefore, the diagnosis and treatment of lipid abnormalities, important aspects of the management of nephrotic children, is summarized here to provide pediatric nephrologists with an informed choice.
引用
收藏
页码:559 / 566
页数:8
相关论文
共 50 条
  • [41] Is rituximab effective in childhood nephrotic syndrome? Yes and no
    Kemper, Markus J.
    Lehnhardt, Anja
    Zawischa, Anna
    Oh, Jun
    PEDIATRIC NEPHROLOGY, 2014, 29 (08) : 1305 - 1311
  • [42] Emerging pharmacotherapies for the treatment of childhood nephrotic syndrome
    Salmon, Eloise
    Trachtman, Howard
    EXPERT OPINION ON PHARMACOTHERAPY, 2025,
  • [43] Histopathological spectrum of childhood nephrotic syndrome in Pakistan
    Muhammed Mubarak
    Ali Lanewala
    Javed Iqbal Kazi
    Fazal Akhter
    Atika Sher
    Amir Fayyaz
    Sajid Bhatti
    Clinical and Experimental Nephrology, 2009, 13 : 589 - 593
  • [44] Apolipoprotein E polymorphism in childhood nephrotic syndrome
    Attila, G
    Noyan, A
    Bayazit, AK
    Acartürk, E
    Anarat, A
    PEDIATRIC NEPHROLOGY, 2002, 17 (05) : 359 - 362
  • [45] The autoimmune architecture of childhood idiopathic nephrotic syndrome
    Al-Aubodah, Tho-Alfakar
    Piccirillo, Ciriaco A.
    Trachtman, Howard
    Takano, Tomoko
    KIDNEY INTERNATIONAL, 2025, 107 (02) : 271 - 279
  • [46] Implication of serum IgE in childhood nephrotic syndrome
    Tain, YL
    Chen, TY
    Yang, KD
    PEDIATRIC NEPHROLOGY, 2003, 18 (12) : 1211 - 1215
  • [47] Cyclosporine versus Cyclophosphamide in Childhood Nephrotic Syndrome
    Khemani, Sunita
    Moorani, Khemchand N.
    JOURNAL OF THE LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, 2016, 15 (02): : 57 - 62
  • [48] Unanswered questions in childhood idiopathic nephrotic syndrome
    Lanewala, Ali
    Mubarak, Muhammed
    JOURNAL OF RENAL INJURY PREVENTION, 2014, 3 (01): : 1 - 2
  • [49] Risk factors for relapse in childhood nephrotic syndrome
    Takeda, A
    Matsutani, H
    Niimura, F
    Ohgushi, H
    PEDIATRIC NEPHROLOGY, 1996, 10 (06) : 740 - 741
  • [50] Rituximab for troublesome cases of childhood nephrotic syndrome
    Osama Y Safdar
    Adila Aboualhameael
    Jameela A Kari
    World Journal of Clinical Pediatrics, 2014, (04) : 69 - 75